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The tumor antigen 5T4/WAIF1 (Wnt-activated inhibi-
tory factor 1; also known as Trophoblast glycopro-
tein TPBG) is a cell surface protein targeted in multi-
ple cancer immunotherapy clinical trials. Recently,
it has been shown that 5T4/WAIF1 inhibits Wnt/
b-catenin signaling, a signaling system central to
many developmental and pathological processes.
Wnt/b-catenin signaling is controlled by multiple in-
hibitors and activators. Here, we report crystal struc-
tures for the extracellular domain of 5T4/WAIF1 at
1.8 A˚ resolution. They reveal a highly glycosylated,
rigid core, comprising eight leucine-rich repeats
(LRRs), which serves as a platform to present
evolutionarily conserved surface residues in the
N-terminal LRR1. Structural and cell-based analyses,
coupled with previously reported in vivo data, sug-
gest that Tyr325 plus the LRR1 surface centered on
a second exposed aromatic residue, Phe97, are
essential for inhibition of Wnt/b-catenin signaling.
These results provide a structural basis for the devel-
opment of 5T4/WAIF1-targeted therapies that pre-
serve or block 5T4/WAIF1-mediated inhibition of
Wnt/b-catenin signaling.
INTRODUCTION
5T4/WAIF1 (also known as trophoblast glycoprotein, TPBG; 5T4
oncofetal trophoblast glycoprotein; and Wnt-activated inhibitory
factor 1, WAIF1) is a vertebrate-specific, single-pass transmem-
brane protein first identified in human placental tissues (Hole and
Stern, 1988). 5T4/WAIF1 is rarely expressed in normal adult tis-
sues, but is present at high levels in placenta and in most com-
mon tumors, typically more than 80% of carcinomas of the
kidney, breast, colon, prostate, and ovary (Hole and Stern,
1988; Southall et al., 1990; Starzynska et al., 1994). Thus, 5T4/
WAIF1 has the characteristics of an oncofetal antigen, high-
lighting it as a possible candidate for use as a diagnostic marker
or target for cancer treatment. A modified vaccinia virus Ankara
(MVA) encoding human 5T4/WAIF1 (designated TroVax or MVA-612 Structure 22, 612–620, April 8, 2014 ª2014 The Authors5T4) induced an antitumor immune response in mouse cancer
models (Woods et al., 2002; Mulryan et al., 2002) and has been
evaluated in clinical trials targeting colorectal cancer, renal cell
carcinoma, and refractory prostate cancer (Kim et al., 2010).
For the most comprehensive phase 3 clinical study of MVA-
5T4 carried out to date (in 733 patients with metastatic renal
cancer), no difference was observed in survival for the overall
study population, but analyses suggested that subgroups of
patients could benefit (Amato et al., 2010). 5T4/WAIF1-targeted
antibody-based therapies are also under active development
(Boghaert et al., 2008; Sapra et al., 2013).
Despite the potential therapeutic value of 5T4/WAIF1 as a
target in oncology, knowledge of the function and molecular
mechanism of action of this cell surface molecule remains
sparse. 5T4/WAIF1 is predicted to contain multiple leucine
rich-repeats (LRRs) in the extracellular domain (Myers et al.,
1994), a transmembrane helix and a cytoplasmic region (Fig-
ure 1A; Figure S1 available online). The cytoplasmic PDZ-binding
motif Ser-Asp-Val of 5T4/WAIF1 has been reported to interact
with the PDZ domain of TIP-2/GIPC (Awan et al., 2002), a cyto-
plasmic protein that associates with vesicles located near the
cell membrane (De Vries et al., 1998). Further downstream
mechanisms of signal transduction remain unknown. Recently,
5T4/WAIF1 has been found to inhibit theWnt/b-catenin signaling
pathway (Kagermeier-Schenk et al., 2011), a key pathway in
embryonic development and a major target for anticancer thera-
peutics (MacDonald et al., 2009; Polakis, 2012). Kagermeier-
Schenk and colleagues (Kagermeier-Schenk et al., 2011)
reported that one of three 5T4/WAIF1 paralogs in zebrafish,
5T4/Waif1a, co-immunoprecipitated with the Wnt coreceptor
LRP6. However, the extracellular domains of 5T4/Waif1a and
LRP6 did not interact directly; this indirect interaction appears
to require colocalization of both partners in the membrane
and/or bridging by an unknown molecule.
5T4/WAIF1 is heavily glycosylated (Hole and Stern, 1988)
posing challenges for production in standard Escherichia coli-
based protein overexpression systems. To date, biophysical
studies of 5T4/WAIF1 are lacking. As a first step in elucidating
the molecular mechanisms governing 5T4/WAIF1 function and
its role in Wnt/b-catenin signaling, we established protocols for
the production of the soluble extracellular domain of 5T4/
WAIF1 (5T4/WAIF1Ecto) using a human embryonic kidney 293
(HEK293) cell-based stable expression system. We determined
three structures of the extracellular domain of 5T4/WAIF1Ecto
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evolutionary, and cell-based analyses, coupled to previously
reported in vivo studies of two zebrafish 5T4/Waif1 paralogs,
5T4/Waif1a and 5T4/Waif1c, reveal key residues of 5T4/WAIF1
that are essential for inhibition of the Wnt/b-catenin signaling
pathway.
RESULTS AND DISCUSSION
Production of the Extracellular Domain of 5T4/WAIF1
Human 5T4/WAIF1 contains 420 amino acid residues and is
a single-pass transmembrane protein (Figures 1A and S1).
Sequence analysis predicts a domain structure comprising
a secretion signal (residues 1–31), serine-rich motif (32–53),
LRRs (60–344), a transmembrane region (356–376), and a short
cytoplasmic tail (377–420; Figure S1). We expressed a full-length
LRR region of 5T4/WAIF1 (D60–D345, 5T4/WAIF1Ecto) with a
C-terminal rhodopsin 1D4 tag (Hodges et al., 1988) as a secreted
construct in HEK293 GnTI() cells (Reeves et al., 2002; Aricescu
et al., 2006; Zhao et al., 2011). A stable cell line was generated by
using a PhiC31 integrase-assisted vector with puromycin selec-
tion, pURD (see Experimental Procedures). We purified 5T4/
WAIF1Ecto using antibody-affinity chromatography followed by
size exclusion chromatography. Multi-angle light scattering
(MALS) analysis indicated that the purified 5T4/WAIF1Ecto was
monomeric in solution (Figure S2A).
Crystal Structures of 5T4/WAIF1Ecto Reveal the LRR
Core Decorated with Loops and Glycans
Enzymatically deglycosylated 5T4/WAIF1Ecto crystallized in two
crystal forms, 1 and 2, with one and two molecules in the asym-
metric unit, respectively (Table 1). Initial crystallographic phases
were calculated by molecular replacement using LRRs of Netrin
G ligand 1 (NGL1; Protein Data Bank [PDB] ID 3ZYJ; Seiradake
et al., 2011) as a search model. Final models from crystal forms
1 and 2 were refined to an Rwork/Rfree of 18.2%/22.2% and
17.7%/21.7% at 1.75 A˚ and 1.77 A˚ resolution, respectively.
All three structures of 5T4/WAIF1Ecto reveal a compact core of
eight LRRs. The LRRs build-up a right-handed slightly twisted
solenoid in which the short b strands are arranged like a ladder
in the concave face of 5T4/WAIF1Ecto (Figures 1B and 1C). The
eight LRRs are flanked by two, N- and C-terminal, cysteine-
rich capping modules (NT-cap and CT-cap, respectively) that
complete the overall structural framework of 5T4/WAIF1Ecto.
The eight LRRs could be classified into three distinct groups (Fig-
ure 1C). LRRs 1–3 and 6 contain a sequence motif Lxx(x)V/
LxxLxLxxxxLxxL/VxxxxF (where x is any amino acid). In LRRs
1–3, the motif provides a scaffold for a rigid hydrophobic core
where three consecutive phenylalanine residues (F111, F138,
and F162) rest on the continuous bed of leucines (Figure 1C).
LRRs 4 and 5 form a second distinct group because they contain
a buried phenylalanine at different positions compared to LRRs
1–3, and 6. A flexible loop (N166–P172) that links LRR 3 to
LRR 4 is ordered only in one out of the three 5T4/WAIF1Ecto
structures, crystal 2, chain B (Figure S3). Similarly, a flexible
insertion (P185–S194) with a short 310 helix is ordered only in
crystal 1 (Figures 1B and S3). Other than these two loops, the
three 5T4/WAIF1Ecto molecules are essentially identical in the
two crystal forms with root mean square deviation (rmsd) of0.17 A˚ for 218 equivalent Ca atoms from crystal 1 and crystal
2, chain A; 0.25 A˚ (231 atoms) for crystal 1 and crystal 2, chain
B (Figure S3). LRRs 7–8 provide a platform onto which the CT-
cap is integrated and contain additional elements (an a helix
C300–E311 at the C terminus of LRR 8; Figure 1C). Finally,
both N- and C-terminal caps contain two disulfide bonds each
that further stabilize the seamless LRR core of 5T4/WAIF1Ecto.
A Potential 5T4/WAIF1-Protein Interaction Hotspot
We investigated the surface characteristics of 5T4/WAIF1Ecto to
delineate the areas that had properties indicative of interaction
sites. Specific protein-protein interactions are rarely mediated
by flexible, heterogeneous glycans. 5T4/WAIF1Ecto contains
seven predicted asparagine-linked glycosylation sites at N81,
N124, N166, N192, N243, N256, and N275 (Figures 1A and
S1). Electron density corresponding to five of these seven poten-
tial glycans is visible in crystal 1 (Figure 1B). The glycan on N166
is not visible because it is located in a disordered loop (N166–
P172); however, fragmentary electron density proximal to N166
is visible in crystal 2, chain B, where loopN166–P172 is stabilized
by a neighboring molecule in the crystal lattice. The glycan on
N192 is not visible, possibly because of flexibility as the putative
site is exposed in solvent channels for both crystal forms. Thus,
our crystal structures suggest that at least five of the putative
N-linked glycosylation sites of 5T4/WAIF1Ecto are glycosylated.
These five glycosylated asparagines therefore flag positions on
the ectodomain structure that are less likely to mediate 5T4/
WAIF1-protein interactions.
The concave face of 5T4/WAIF1Ecto contains an extended,
negatively charged region that spans five LRRs: E177 in LRR4;
E216, LRR5; D240 LRR6; E266 and D267, LRR7; and D292,
LRR8 (Figure 1D). This region is bordered by the glycosylated
N124 on LRR2 and an array of positively charged residues:
R213, R214, R237, H238, H264, and R288. These residues
bind sulfate ions in crystal form 2 (Figure 1E). Notably, similar
positively charged surfaces mediate interactions among Wnts,
their inhibitors, and heparan sulfate proteoglycans (HSPG; Mali-
nauskas et al., 2011), suggesting that 5T4/WAIF1 interactions
with its binding partners could be modulated by HSPGs. 5T4/
WAIF1Ecto did not bind to a heparin column (Figure S2B), consis-
tent with the calculated isoelectric point of 5.36, arguing against
5T4-heparan sulfate interactions. However, this finding does not
exclude the possibility that charged regions of 5T4/WAIF1 could
interact with HSPGs and/or other proteins.
Protein-protein interactions are frequently mediated by rigid,
larger than 600 A˚2 surfaces enriched in aromatic, evolutionarily
conserved residues (Moreira et al., 2007). 5T4/WAIF1Ecto has
five aromatic side chains (F97, Y224, Y251, F290, and Y325)
exposed on its surface (Figure 1F). We further investigated which
surface exposed residues of 5T4/WAIF1 are conserved across
5T4/WAIF1 family members in vertebrates. Notably, a cluster
of evolutionarily conserved residues (E67, S69, and K76) is
centered on F97 of LRR1 (Figure 1F). Thus F97 represents a
potential ‘‘hot spot’’ thatmightmediate 5T4/WAIF1-protein inter-
actions and/or might be important for the inhibition of Wnt/b-cat-
enin signaling by 5T4/WAIF1. Similarly, the aromatic character of
Y325 is conserved, and mammalian 5T4/WAIF1 sequences and
zebrafish Waif1a contain either tyrosine or phenylalanine at this
position.Structure 22, 612–620, April 8, 2014 ª2014 The Authors 613
(legend on next page)
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Functionally Related Proteins
In a second approach to identify where the potential ligand-
binding regions of 5T4/WAIF1 are located, we compared 5T4/
WAIF1Ecto to other structures of LRR-containing proteins and
their complexes. We used the secondary structure matching
program PDBeFold (Krissinel and Henrick, 2004) for protein
structure alignment to identify the closest structural homologs
of 5T4/WAIF1Ecto. The most similar protein is Netrin G ligand 1
(NGL1; PDB ID 3ZYJ, chain A), which binds to Netrin G1 via
its concave surface (Figure 1G; Seiradake et al., 2011). 5T4/
WAIF1Ecto and NGL1 could be superimposed based on 222
equivalent Ca atoms with an rmsd of 2.0 A˚, highlighting the over-
all conservation of the capped LRR fold. Despite this structural
similarity, the sequence identity between 5T4/WAIF1 and
NGL1 is low (10%) and provides no evidence for any similarity
in protein-binding mode. A second structurally similar protein,
glycoprotein 1ba (PDB ID 1P9A, chain G; rmsd 2.3 A˚ for 225
equivalent Ca atoms), recognizes its ligand, thrombin, using a
combination of flexible C-terminal tail and two LRRs (Celikel
et al., 2003). Glycoprotein 1bawraps around one side of another
ligand, von Willebrand factor A1 domain, using N- and C-termi-
nal b-fingers that are absent in 5T4/WAIF1Ecto (Huizinga et al.,
2002).
5T4/WAIF1Ecto lacks surfaces or sequencemotifs that are pre-
sent in other extracellular inhibitors or receptors of the Wnt
signaling pathway. It does not have the surface-exposed NxI
motif that mediates interactions between the Wnt co-receptor
LRP6 and two inhibitors, Dickkopf and Sclerostin (Bourhis
et al., 2011). There is an absence of hydrophobic grooves (pre-
sent in Wnt8 receptor Frizzled8, Janda et al., 2012) or pockets
(present in the Wnt inhibitory factor 1; Malinauskas, 2008; Mali-
nauskas et al., 2011) that couldmediate 5T4/WAIF1Ecto inhibitory
function by sequestering Wnt-linked palmitoleyl moieties. The
only other inhibitor of Wnt signaling that has a LRR fold is Tsu-
kushi, which functions as a Wnt signaling inhibitor by competing
with Wnt protein for binding to the receptor Frizzled4 (Ohta et al.,
2011). However, the sequence identity between 5T4/WAIF1 and
Tsukushi is relatively low, 20%, suggesting that the mode of
Wnt inhibition may be different. Taken together, our comparison
of 5T4/WAIF1 to other LRR-containing protein recognition mod-
ules and inhibitors of Wnt signaling suggests that 5T4/WAIF1 is aFigure 1. Crystal Structure of the Human 5T4/WAIF1Ecto
(A) Domain organization of human 5T4/WAIF1. Seven glycosylation sites are m
serine-rich and transmembrane regions are gray.
(B) Ribbon diagram of 5T4/WAIF1Ecto in two views that differ by a 90
 rotation a
glucosamines are shown as magenta sticks. Disulfide bonds are shown as gray
(C) The structure-based alignment of LRRs of 5T4/WAIF1Ecto reveals repetitive pa
build up the framework of 5T4/WAIF1Ecto. LRRs 1–3 and LRR6 form a distinctive
panel), which contributes to the tightly packed hydrophobic core of 5T4/WAIF1E
stabilized by hydrogen bonding patterns between multiple, three residue-long b
(D) Electrostatic properties of 5T4/WAIF1Ecto. The protein is shown as solvent-acc
basic). The orientation of 5T4/WAIF1Ecto on the left side is the same as in (B, left sid
the text are indicated.
(E) A highly charged, sulfate-binding region on LRRs 5–8, colored as in (B). Side ch
to orange; nitrogen, blue; sulfur, yellow; oxygen, red). Distances between atoms
(F) The surface of 5T4/WAIF1Ecto is colored by residue conservation (conserved,
were included in the sequence conservation analysis. Five surface-exposed arom
(G) Superposition of 5T4/WAIF1Ecto (green) onto Netrin G ligand 1 (NGL1; blue) in c
of LRRs to recognize LRR-binding proteins.unique antagonist of Wnt signaling. Our analysis of evolutionarily
conserved surface residues (see previous section) had identified
a putative protein-binding hotspot; therefore, we focused further
analyses onto this region, which encompasses the NT-cap and
LRR1. It contains the surface exposed side chains of S69, E67,
T74, K76, N95, and, most notably, F97 (Figures 2A and 2B).
Lys76 and Phe97 of 5T4/WAIF1 Are Essential for the
Inhibition of Wnt Signaling
We used a cell-based Wnt/b-catenin signaling assay (DasGupta
et al., 2005) to investigate the role of the conserved surface res-
idues clustered around F97 of human 5T4/WAIF1 (Figure 2).
Based on our crystal structures, we selected residues for site-
directed mutagenesis that have their side chains exposed on
the exterior of 5T4/WAIF1 and are therefore less likely to disturb
the overall structural integrity (Figure 2A). Most full-length, wild-
type and mutant, 5T4/WAIF1 constructs were trafficked to the
cell membrane as assessed by fluorescence microscopy (Fig-
ure S4A), except two variants, N124Q and R214E, which were
not secreted as 5T4/WAIF1Ecto constructs. Wild-type and
mutant extracellular domains were expressed and secreted at
similar levels (except N124Q and R214E) as assessed by west-
ern blot and FACS analyses (Figures S4B and S4C), consistent
with them all being folded, glycosylated, and passing cellular
quality control systems (Trombetta and Parodi, 2003).
Consistent with previous studies (Kagermeier-Schenk et al.,
2011), conditioned media containing secreted mouse Wnt3a
activated theWnt/b-catenin signaling pathway in HEK293T cells,
and this signaling was inhibited both by theWnt antagonist Dick-
kopf (a positive control) and wild-type 5T4/WAIF1 (Figures 2C
and S5). Combined mutations of two residues, N338A and
A340G, exposed at the CT-cap did not have an effect on the
inhibitory function of 5T4/WAIF1 (Figures 2A and 2C). Similarly,
combined mutations E189R, R190A, and Q191A in an evolution-
arily divergent region, the flexible insertion in LRR4 (Figures 1B,
1C, 2A, and 2C), did not affect the 5T4/WAIF1-mediated
inhibition.
We investigated two sulfate ion-contacting residues, R214
and E261, using charge reversal mutations, R214E and E261R,
respectively (Figure 1E). E261R did not have an effect on the
Wnt-inhibitory function of 5T4/WAIF1 (Figures 2C and S5),
whereas R214E abolished secretion of 5T4/WAIF1Ecto R214Earked with hexagons. The 5T4/WAIF1Ecto is colored in blue-to-red transition;
round a vertical axis. 5T4/WAIF1Ecto is colored as in (A). Asn-linked N-acetyl-
connected spheres.
tterns of leucines (or similar hydrophobic residues, valines, and isoleucine) that
group; each of these LRRs contains a buried phenylalanine (pink in the bottom
cto. On top of the LRR-based core, the architecture of 5T4/WAIF1Ecto is further
strands (highlighted in gray background).
essible surface colored by electrostatic potential at ± 5 kT/e (red, acidic; blue,
e). Glycanmoieties are shown as yellow sticks. Charged residues discussed in
ains of sulfate-binding residues are labeled and shown as sticks (carbons, gray
are shown in angstroms.
magenta; variable, cyan). Sequences of 45 members of the 5T4/WAIF1 family
atic residues are indicated; only one, F97, is evolutionarily conserved.
omplex with Netrin G1 (gray surface) illustrates the potential of the concave face
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Table 1. X-Ray Crystallography Data Collection and Refinement
Statistics
5T4/WAIF1Ecto
(Crystal Form 1)
5T4/WAIF1Ecto
(Crystal Form 2)
Data Collection
X-ray source Diamond Light
Source, beamline I02
Diamond Light
Source, beamline I02
Wavelength (A˚) 1.06 1.06
Resolution range (A˚) 49.31–1.75
(1.80–1.75)
54.33–1.77
(1.82–1.77)
Space group P 21 21 21 P 1 21 1
Unit cell
a, b, c (A˚) 49.31, 67.31, 96.38 49.6, 95.82, 65.97
a, b, g () 90, 90, 90 90, 91.14, 90
Total reflections 317,855 300,698 (21,206)
Unique reflections 33,062 59,830 (4,362)
Multiplicity 9.6 (9.3) 5.0 (4.9)
Completeness (%) 99.8 (99.2) 99.7 (99.5)
Mean I/sigma (I) 17.9 (3.1) 13.8 (2.5)
Rmerge (all I
+ and I) (%)a 6.6 (81.3) 6.3 (76.4)
Refinement
Resolution range (A˚) 43.94–1.75
(1.80–1.75)
54.33–1.77
(1.82–1.77)
Number of reflections,
work/test set
31,330/1,674 56,784/3,022
Number of atoms
(protein/ligands,
glycans/waters)
2,493 (2,239/
130/124)
4,712 (4,276/
257/179)
Protein residues 283 552
Mean B-factors
(protein/ligands,
glycans/waters) (A˚2)
36 (35/55/40) 32 (32/52/37)
Rwork (%) 18.2 (27.9) 17.7 (24.5)
Rfree (%) 22.2 (29.4) 21.7 (29.8)
Rmsd from ideal
values (bonds) (A˚)
0.016 0.016
Rmsd from ideal
values (angles, )
1.8 1.9
Ramachandran plotb
Favored regions (%) 95.7 95.4
Outliers (%) 0.0 0.2
Values for the highest resolution shell are shown in parentheses.
aAs defined in Aimless (Evans and Murshudov, 2013).
bAs defined in MolProbity (Chen et al., 2010).
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Inhibition of Wnt Signaling by Cancer Antigen 5T4(Figure S4B), suggesting aberrant trafficking of this construct
within the cell. Consistent with these observations, 5T4/WAIF1
R214E did not inhibit Wnt signaling (Figures 2C and S5). We
note that positive charge at the position corresponding to
R214 in human 5T4/WAIF1 is relatively conserved across spe-
cies (Arg/Lys/His in 11 of 15 species; Figure S1), suggesting
that the charge characteristics of this position play a role in the
folding and trafficking of 5T4/WAIF1.
Similarly to R214E, mutation of glycosylated N124 to
glutamine impaired trafficking to the cell surface and Wnt-
inhibitory function of full-length 5T4/WAIF1 N124Q (Figures616 Structure 22, 612–620, April 8, 2014 ª2014 The AuthorsS4A and 2C, respectively). Consistent with the behavior of
the full-length protein, 5T4/WAIF1Ecto N124Q was not secreted
(Figure S4B).
Mutation of the highly conserved phenylalanine residue, F97,
to threonine (F97T) significantly (p = 0.0002) reduced the Wnt-
inhibitory function of human 5T4/WAIF1 (Figure 2C). The side
chain of F97 is sandwiched between the glycosylated N124
and evolutionarily conserved K76 (Figure 2B). The juxtaposition
of F97 and K76 could provide further stabilization to this region
because of cation-p interactions between the -NH3
+ group of
K76 and the adjacent delocalized electrons of F97, respectively
(Gallivan and Dougherty, 1999). The average distance between
the nitrogen of the K76 side chain and the carbon atoms of the
F97 ring is 5.4 A˚ (SD, 0.3 A˚) in the two crystal forms. Indeed,
5T4/WAIF1 mutant K76A inhibited Wnt signaling significantly
(p < 0.0001) less efficiently compared to wild-type 5T4/WAIF1
in our cell-based assay (Figure 2C). Mutation of the less
conserved N95 to alanine did not influence the Wnt-inhibitory
function. Interestingly, a similar lack of effect on function was
observed for a mutation, T74V, of the conserved T74 (Figure 2C).
Thus, while sensitive to mutation of F97 and K76, the inhibitory
function of 5T4/WAIF1 appears relatively robust to mutation of
neighboring residues (Figures 2B and 2C). Mutants E67A and
S69A also showed less marked effects on Wnt-inhibitory func-
tion than F97T and K76A (Figure 2C).
In addition, we tested the effect of mutation Y325A on
the Wnt-inhibitory function of 5T4/WAIF1. Multiple vertebrates
contain phenylalanine at the corresponding position, including
zebrafish Wnt-inhibitory Waif1a (F274; zebrafish noninhibitory
Waif1c contains S283 at the equivalent position; Figure S1).
5T4/WAIF1Ecto Y325A was expressed and secreted at a similar
level compared to wild-type 5T4/WAIF1Ecto (Figure S4). The full-
length 5T4/WAIF1 Y325A did not inhibit Wnt3a signaling in the
cell-based assay (Figures 2C and S5), suggesting that, in addi-
tion to the region around F97 and K76, other surfaces of 5T4/
WAIF1 may be important for the inhibition of Wnt signaling.
Notably, the surface proximal to Y325 is not obstructed by
Asn-linked glycosylation and thus may be accessible for the in-
teractions between 5T4/WAIF1 and currently unknown binding
partners.
Our results suggest that residues K76 and F97 are essential
for the inhibition of the Wnt/b-catenin signaling pathway by hu-
man 5T4/WAIF1. The previously reported findings for zebrafish
paralogs 5T4/Waif1a and 5T4/Waif1c (Kagermeier-Schenk
et al., 2011) shed new light when revisited in the context of
our data. Whereas 5T4/Waif1a inhibited Wnt/b-catenin sig-
naling, 5T4/Waif1c did not. A chimera comprising the 5T4/
Waif1a ectodomain plus 5T4/Waif1c cytoplasmic domain in-
hibited Wnt signaling, whereas the 5T4/Waif1c ectodomain
plus 5T4/Waif1a transmembrane and cytoplasmic regions did
not inhibit. These results indicated that the 5T4/Waif1 cyto-
plasmic region is dispensable for Wnt signaling inhibition;
however, they also raise the question as to which differences
between the ectodomains of 5T4/Waif1a and 5T4/Waif1c are
responsible for the difference in inhibitory function. We therefore
analyzed the ectodomain sequences (Figure 2D). We found that
the Wnt-inhibitory 5T4/Waif1a in zebrafish has K40, F61, and
F274 at the positions corresponding to K76, F97, and Y325 in
human 5T4/WAIF1. In contrast, the noninhibitory 5T4/Waif1c
Figure 2. An Evolutionarily Conserved Re-
gion of 5T4/WAIF1Ecto Is Essential for the
Inhibition of the Wnt Signaling Pathway
(A) The surface of the 5T4/WAIF1Ecto is colored by
residue conservation as in Figure 1F. Residues
investigated in the Wnt-responsive cell-based
assay are indicated.
(B) A surface-exposed region that mediates the
Wnt-inhibitory function of 5T4/WAIF1. b Strands
of 5T4/WAIF1Ecto are colored as in Figure 1B,
numbering corresponds to Figure S1.Nitrogen and
oxygen atoms of selected side chains and glycans
are shown in blue and red, respectively. Disulfide
bonds are shown as gray connected spheres.
(C) The inhibition of Wnt3a signaling in a cellular
assay by wild-type and mutant constructs of 5T4/
WAIF1 and the Wnt inhibitor Dickkopf. The
signaling was induced using conditioned media
containing secreted mouse Wnt3a. Wnt3a sig-
naling was inhibited by wild-type 5T4/WAIF1 and
Dickkopf, but it was significantly less inhibited by
5T4/WAIF1 mutant constructs K76A and F97N.
The experiment was repeated three times (results
from experiment 1 are shown here, from experi-
ments 2 and 3; Figure S5), each time in quadru-
plicate, and error bars showSD. The p valueswere
calculated using paired t test are shown for the
wild-type K76A, F97T, and Y325A pairs. The other
mutant constructs of 5T4/WAIF1 did not show
significant inhibition of Wnt signaling as suggested
by p values (p > 0.05). Columns corresponding to
twomutant constructsof 5T4/WAIF1 that exhibited
impaired trafficking to the cell surface (N124Q and
R214E; Figure S4) are shown in gray.
(D) Amino acid sequence alignment of the N-ter-
minal regions of the 5T4/WAIF1 family members.
K76 and F97, which are essential for the Wnt-
inhibitory function of human 5T4/WAIF1 (Fig-
ure 2C), are marked with red stars. Corresponding
residues N52 and N73 in the noninhibitory 5T4/
Waif1c from zebrafish are framed in black.
Boundaries between the NT-cap, LRR1, and
LRR2 are shown below the alignment. An align-
ment of the full-length 5T4/WAIF1 proteins is
presented in Figure S1.
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Inhibition of Wnt Signaling by Cancer Antigen 5T4has N52, N73, and S283 at the corresponding positions, further
supporting the notion that these surface-exposed residues play
a key role in the inhibition of Wnt/b-catenin signaling by 5T4/
WAIF1 family members.
FutureDirections and Implications for Cancer Therapies
Our structural, evolutionary, and cell-based analyses, combined
with previously reported in vivo studies in zebrafish (Kagermeier-
Schenk et al., 2011), suggest that the conserved surface
centered on K76 and F97, plus a second area involving Y325,
is essential for the inhibition of the Wnt/b-catenin signaling
pathway by human 5T4/WAIF1. However, the proteins that
bind to these surfaces remain to be identified. The protocols
we report here for the production of wild-type and mutant 5T4/
WAIF1 proteins could provide useful reagents for the identifica-
tion and validation of 5T4/WAIF1 binding partners (cf. the
strategy of So¨llner and Wright, 2009), to add further intriguing in-
sights into the variedmechanisms bywhichWnt signaling can be
modulated. Our studies detail the specific atomic-level featuresthat link 5T4/WAIF1, a tumor antigen that is the focus of multiple
late phase clinical trials, with the Wnt signaling pathway, a well-
established but challenging target in oncology (Polakis, 2012).
These data provide a structural basis for the assessment of cur-
rent therapeutic anti-5T4/WAIF1 antibodies (Boghaert et al.,
2008; Sapra et al., 2013) in terms of their ability to preserve or
block 5T4/WAIF1-mediated inhibition of Wnt/b-catenin signaling
with consequent benefits and risks.EXPERIMENTAL PROCEDURES
Protein Production
We cloned human 5T4/WAIF1 (UniProtKB/Swiss-Prot Q13641) extracellular
domain (residues D60–D345) construct 5T4/WAIF1Ecto from the IMAGE clone
438906 (Source BioScience) into a stable cell line generation vector pURD that
we had recently engineered in-house (Figure S6). HEK293S GnTI() cells
(Reeves et al., 2002) were cotransfected with pURD-5T4/WAIF1Ecto and
a PhiC31 integrase expression vector (pgk-phiC31). The polyclonal cell popu-
lation resulting from puromycin (2 mg/ml) selection was used for the protein
production. The secreted 5T4/WAIF1Ecto protein has additional amino acidsStructure 22, 612–620, April 8, 2014 ª2014 The Authors 617
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quences (last nine residues are Rhodopsin 1D4 tag; Molday and MacKenzie,
1983). For protein purification, the conditioned media were passed through
the anti-1D4 tag antibody (University of British Columbia) covalently linked
to Sepharose beads at 4C (CNBr-activated Sepharose 4 Fast Flow, GE
Healthcare) and eluted with 1D4 peptide. For deglycosylation, 5T4/WAIF1Ecto
was treated with endo-b-N-acetylglucosaminidase F1 (37C, 1 hr) and further
purified by size-exclusion chromatography (Superdex 200 16/60 column, GE
Healthcare) in 20 mM Tris-HCl, pH 7.5, and 150 mM NaCl.
Crystallization and Structure Determination
5T4/WAIF1Ecto was concentrated to 5.5 mg/ml and crystallized using the
sitting drop, vapor diffusion method at 21C (Walter et al., 2005). The crystal-
lization drop contained 100 nl of concentrated 5T4/WAIF1Ecto, 100 nl of
25% w/v polyethylene glycol (PEG) 3350, 0.1 M citrate pH 3.5, and 0.5 nl of
0.1 M NaOH (crystal form 1). For crystal form 2, the crystallization drop con-
tained 100 nl of concentrated 5T4/WAIF1Ecto plus 100 nl of 0.2 M (NH4)2SO4,
30% w/v PEG 4000. Crystals were flash-frozen by immersion into a reservoir
solution supplemented with 25% v/v glycerol followed by transfer to liquid
nitrogen. The crystals were kept at 173C during X-ray diffraction data
collection. Diffraction data were indexed and integrated using XDS (Kabsch,
2010), and scaled and merged using Aimless (Evans and Murshudov, 2013).
Initial X-ray phases were determined by molecular replacement using the
NGL1 structure (PDB ID 3ZYJ; Seiradake et al., 2011) as a search model in
Phaser (McCoy et al., 2007). Structures were built using Buccaneer (Cowtan,
2008), PHENIX AutoBuild (Terwilliger et al., 2008), further refined in REFMAC
(Murshudov et al., 1997), validated using MolProbity (Chen et al., 2010), and
analyzed using ConSurf (Glaser et al., 2003) and the PyMOL Molecular
Graphics System (Schro¨dinger). Data collection and refinement statistics
are shown in Table 1.
Multi-Angle Light Scattering Analysis
MALS analysis of 5T4/WAIF1Ecto was performed during analytical size exclu-
sion chromatography using Superdex 75 10/300 GL column (GE Healthcare
Life Sciences) connected to static light-scattering (DAWN HELEOS II, Wyatt
Technology), differential refractive index (Optilab rEX, Wyatt Technology),
and Agilent 1200 UV (Agilent Technologies) detectors. Purified 5T4/WAIF1Ecto
(2.24 mg/ml, 0.1 ml) was loaded onto a column equilibrated in 150 mM NaCl,
10mMHEPES, at pH 7.5. Datawere analyzed using the ASTRA software pack-
age (Wyatt Technology).
Heparin Affinity Chromatography
Purified 5T4/WAIF1Ecto (0.358 mg/ml, 0.69 ml) was loaded onto a 5 ml HiTrap
heparin HP column (GE Healthcare Life Sciences) equilibrated in 40 mMNaCl,
10 mM HEPES, and pH 7.5. Elution of 5T4/WAIF1Ecto (flow rate 2 ml/min) was
followed by absorption at 280 nm. A linear NaCl gradient, from 40 mM NaCl,
10 mM HEPES, pH 7.5 to 1 M NaCl, 10 mM HEPES, pH 7.5 over ten column
volumes was applied but 5T4/WAIF1Ecto did not bind to the column and was
eluted with 40 mM NaCl, 10 mM HEPES, at pH 7.5.
Cellular Assays for Wnt Signaling
Wnt3a-responsive cell-based assays were carried out using HEK293T cells
in quadruplicate (in 96-well plates, 105 cells/well). Cells were cotransfected
with a SuperTopFlash firefly luciferase plasmid (300 ng/well; DasGupta
et al., 2005), a constitutive Renilla luciferase plasmid (pRL-TK from Promega
100 ng/well), and a 5T4/WAIF1 wild-type (residues 1–420, cloned into the
pneo-sec vector via EcoR1 and Xho1 sites; pneo-sec is similar to pHLsec
[Aricescu et al., 2006], but it contains a neomycin/kanamycin resistance
selection marker) or a mutation variant or Dkk plasmid (Chen et al., 2011;
300 ng/well). Lipofectamine 2000 (Invitrogen) was used according to the
manufacturer’s recommendations. Sixteen hours after transfection, the
media were replaced with the conditioned media from the mouse L-Wnt3a
cell line for Wnt signaling induction. The firefly and Renilla luciferase activities
were measured 24 hr later with the Dual-Glo luciferase reporter assay
system (Promega) using an Ascent Lunimoskan luminometer (Labsystems).
The enzymatic activity of firefly luciferase was normalized compared to
constitutive Renilla luciferase activity.618 Structure 22, 612–620, April 8, 2014 ª2014 The AuthorsExpression Analysis of 5T4/WAIF1 Constructs
For western blot analyses of secreted 5T4/WAIF1 constructs, residues 32–355
were cloned into a modified pHLsec vector with a C-terminal 1D4 tag and ex-
pressed in HEK293T cells for 2 days. 5T4/WAIF1 samples (cell lysates and
conditioned media) were reduced with dithiothreitol and heated for 5 min
at 100C before loading on the SDS-PAGE gels. Western blots were probed
with mouse anti-1D4 tag (University of British Columbia), anti-His tag (Penta
His, QIAGEN), anti-a-tubulin (Sigma), and anti-b-actin (Abcam) antibodies,
followed by goat anti-mouse IgG-horseradish peroxidise (HRP) conjugate
(Sigma). HRP was detected using the Amersham ECL western blotting detec-
tion kit (GE Healthcare Life Sciences). For the expression analysis of human
5T4/WAIF1 on the cell surface, wild-type and mutant constructs (residues
32–420) were cloned into a modified pHLsec vector (pHLsec-mVenus), which
has a C-terminal monomeric fluorescent protein mVenus (Nagai et al., 2002)
tag (a gift from A. Clayton and A. R. Aricescu, Oxford) and expressed in
COS-7 cells for 2 days. Images of the cells were taken using the Leica
SP8-X SMD inverted microscope.
Flow cytometry analysis of 5T4/WAIF1 tagged with a fluorescent mono-
Venus protein was performed in HEK293T cells. The expression of mono-
Venus was monitored via flow cytometry on a CyAn ADP Analyzer (Beckman
Coulter). The argon-ion laser was tuned to 488 nm with 100 mW of
power, and mono-Venus fluorescence detected in FL1 through a 530/
40-nm bandpass filter. Data analysis was performed using FlowJo software
(Tree Star).ACCESSION NUMBERS
The PDB accession numbers for the structure factors and coordinates corre-
sponding to the crystal forms 1 and 2 of 5T4/WAIF1Ecto are 4CNM and 4CNC,
respectively.SUPPLEMENTAL INFORMATION
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